Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

doi:10.1001/jama.2023.19574

. 2023 Nov 14;330(18):1795-1797.

doi: 10.1001/jama.2023.19574.

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Mohit Sodhi¹, Ramin Rezaeianzadeh¹, Abbas Kezouh², Mahyar Etminan³

Affiliations

¹ Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
² StatExpert Ltd, Laval, Quebec, Canada.
³ Department of Ophthalmology and Visual Sciences and Medicine, University of British Columbia, Vancouver, Canada.

PMID: 37796527
PMCID: PMC10557026
DOI: 10.1001/jama.2023.19574

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Mohit Sodhi et al. JAMA. 2023.

. 2023 Nov 14;330(18):1795-1797.

doi: 10.1001/jama.2023.19574.

Authors

Mohit Sodhi¹, Ramin Rezaeianzadeh¹, Abbas Kezouh², Mahyar Etminan³

Affiliations

¹ Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
² StatExpert Ltd, Laval, Quebec, Canada.
³ Department of Ophthalmology and Visual Sciences and Medicine, University of British Columbia, Vancouver, Canada.

PMID: 37796527
PMCID: PMC10557026
DOI: 10.1001/jama.2023.19574

No abstract available

Plain language summary

This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Comment in

GLP-1 Receptor Agonists and Gastrointestinal Adverse Events.
Suissa K, Cromer SJ, Patorno E. Suissa K, et al. JAMA. 2024 Mar 12;331(10):884-885. doi: 10.1001/jama.2024.0046. JAMA. 2024. PMID: 38470390 No abstract available.

Cited by

Comparative analysis of semaglutide induced adverse reactions: Insights from FAERS database and social media reviews with a focus on oral vs subcutaneous administration.
Zhang J, Wang X, Zhou Y. Zhang J, et al. Front Pharmacol. 2024 Oct 22;15:1471615. doi: 10.3389/fphar.2024.1471615. eCollection 2024. Front Pharmacol. 2024. PMID: 39502525 Free PMC article.
Characterization and potential health benefits of millet flour and banana peel mixtures on rats fed with a high-fat diet.
Alshehri AA, Younes NM, Kamel R, Shawir SM. Alshehri AA, et al. Heliyon. 2024 Oct 16;10(20):e39424. doi: 10.1016/j.heliyon.2024.e39424. eCollection 2024 Oct 30. Heliyon. 2024. PMID: 39497975 Free PMC article.
GLP-1 Receptor Agonists and Risk of Paralytic Ileus: A drug-target Mendelian Randomization Study.
Ding P, Gao Z, Gorenflo MP, Xu R. Ding P, et al. medRxiv [Preprint]. 2024 Oct 17:2024.10.17.24315627. doi: 10.1101/2024.10.17.24315627. medRxiv. 2024. PMID: 39484277 Free PMC article. Preprint.
Food-induced small bowel obstruction observed in a patient with inappropriate use of semaglutide.
Itoh Y, Tani M, Takahashi R, Yamamoto K. Itoh Y, et al. Diabetol Int. 2024 Sep 9;15(4):850-854. doi: 10.1007/s13340-024-00751-4. eCollection 2024 Oct. Diabetol Int. 2024. PMID: 39469548
A Saudi Heart Association Position Statement on Obesity and Cardiovascular Disease.
Alhabeeb W, Kinsara AJ, Bakhsh A, Tash A, Alshammary A, Almasood A, Alghalayini K, Arafah M, Hamdy O, Alsifri S, Kharabsheh SM, Alkattan W. Alhabeeb W, et al. J Saudi Heart Assoc. 2024 Oct 2;36(3):263-300. doi: 10.37616/2212-5043.1391. eCollection 2024. J Saudi Heart Assoc. 2024. PMID: 39469000 Free PMC article.

See all "Cited by" articles

References

1. Sauer N, Reining F, Schulze Zur Wiesch C, Burkhardt T, Aberle J. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice. Horm Metab Res. 2015;47(8):560-564. - PubMed
1. Rubino DM, Greenway FL, Khalid U, et al. ; STEP 8 Investigators . Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619 - DOI - PMC - PubMed
1. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1–based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534-539. doi:10.1001/jamainternmed.2013.2720 - DOI - PubMed
1. Gudin B, Ladhari C, Robin P, et al. . Incretin-based drugs and intestinal obstruction: a pharmacovigilance study. Therapie. 2020;75(6):641-647. doi:10.1016/j.therap.2020.02.024 - DOI - PubMed
1. Kalas MA, Galura GM, McCallum RW. Medication-induced gastroparesis: a case report. J Investig Med High Impact Case Rep. 2021;9:23247096211051919. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information

[1] Sauer N, Reining F, Schulze Zur Wiesch C, Burkhardt T, Aberle J. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice. Horm Metab Res. 2015;47(8):560-564. - PubMed

[2] Sauer N, Reining F, Schulze Zur Wiesch C, Burkhardt T, Aberle J. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice. Horm Metab Res. 2015;47(8):560-564. - PubMed

[3] Rubino DM, Greenway FL, Khalid U, et al. ; STEP 8 Investigators . Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619 - DOI - PMC - PubMed

[4] Rubino DM, Greenway FL, Khalid U, et al. ; STEP 8 Investigators . Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619 - DOI - PMC - PubMed

[5] Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1–based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534-539. doi:10.1001/jamainternmed.2013.2720 - DOI - PubMed

[6] Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1–based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534-539. doi:10.1001/jamainternmed.2013.2720 - DOI - PubMed

[7] Gudin B, Ladhari C, Robin P, et al. . Incretin-based drugs and intestinal obstruction: a pharmacovigilance study. Therapie. 2020;75(6):641-647. doi:10.1016/j.therap.2020.02.024 - DOI - PubMed

[8] Gudin B, Ladhari C, Robin P, et al. . Incretin-based drugs and intestinal obstruction: a pharmacovigilance study. Therapie. 2020;75(6):641-647. doi:10.1016/j.therap.2020.02.024 - DOI - PubMed

[9] Kalas MA, Galura GM, McCallum RW. Medication-induced gastroparesis: a case report. J Investig Med High Impact Case Rep. 2021;9:23247096211051919. - PMC - PubMed

[10] Kalas MA, Galura GM, McCallum RW. Medication-induced gastroparesis: a case report. J Investig Med High Impact Case Rep. 2021;9:23247096211051919. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Affiliations

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Authors

Affiliations

Plain language summary

Conflict of interest statement

Comment in

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Plain language summary

Conflict of interest statement

Comment in

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical